

*Discovery of DGAT2 Inhibitors for the Treatment of NASH*

**Kentaro Futatsugi**, Pfizer

**Abstract:**

This presentation will cover a discovery story of DGAT2 inhibitors for the treatment of NASH through three generations of preclinical candidates, ultimately leading to Ervogastat (PF-06865571), a first-in-class small molecule clinical asset for DGAT2 inhibition currently in phase 2 clinical trials both as a monotherapy and as a combination with a liver-targeted ACC inhibitor Clesacostat (PF-05221304). The presentation will focus on preclinical discovery and medicinal chemistry optimizations based on hypothesis-driven, property-based drug designs.